UMIN-CTR Clinical Trial

Recruitment status Terminated
Unique ID issued by UMIN UMIN000019666
Receipt No. R000022725
Scientific Title Genomic Analysis of Circulating Tumor Cells in Patients with Small Cell Lung Cancer
Date of disclosure of the study information 2015/11/09
Last modified on 2019/11/14 (Ver. 4)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Genomic Analysis of Circulating Tumor Cells in Patients
with Small Cell Lung Cancer
Acronym Genomic Analysis of Circulating Tumor Cells in Patients
with Small Cell Lung Cancer
Scientific Title Genomic Analysis of Circulating Tumor Cells in Patients
with Small Cell Lung Cancer
Scientific Title:Acronym Genomic Analysis of Circulating Tumor Cells in Patients
with Small Cell Lung Cancer
Region
Japan

Condition
Condition Small Cell Lung Cancer
Classification by specialty
Pneumology Hematology and clinical oncology
Classification by malignancy Malignancy
Genomic information YES

Objectives
Narrative objectives1 Genomic Analysis of Circulating Tumor Cells in Patients
with Small Cell Lung Cancer
Basic objectives2 Others
Basic objectives -Others Genomic Analysis of Circulating Tumor Cells in Patients
with Small Cell Lung Cancer
Trial characteristics_1 Exploratory
Trial characteristics_2 Others
Developmental phase Not applicable

Assessment
Primary outcomes genomic analysis of circulating tumor cells in patients
with small cell lung cancer by collecting blood samples at pre-, and post- treatment.
Key secondary outcomes

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria patients newly diagnosed as having SCLC and starting chemotherapy or chemoradiotherapy
Key exclusion criteria <20 years old
Target sample size 60

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Yamaoka Toshimitsu
Organization Showa University
Division name institute of molecular oncology
Zip code
Address 1-5-8 Hatanodai, Shinagawa-ku, Tokyo
TEL 03-3784-8146
Email yamaoka.t@med.showa-u.ac.jp

Public contact
Name of contact person
1st name
Middle name
Last name Yamaoka Toshimitsu
Organization Showa University
Division name institute of molecular oncology
Zip code
Address 1-5-8 Hatanodai, Shinagawa-ku, Tokyo
TEL 03-3784-8146
Homepage URL
Email yamaoka.t@med.showa-u.ac.jp

Sponsor
Institute Yamaoka Toshimitsu
Institute
Department

Funding Source
Organization Showa University
Organization
Division
Category of Funding Organization Other
Nationality of Funding Organization

Other related organizations
Co-sponsor Center for Antibody and Vaccine Therapy,
Research Hospital, The Institute of Medicine,
University of Tokyo
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2015 Year 11 Month 09 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Terminated
Date of protocol fixation
2015 Year 11 Month 09 Day
Date of IRB
2015 Year 10 Month 28 Day
Anticipated trial start date
2015 Year 11 Month 09 Day
Last follow-up date
2019 Year 11 Month 14 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information patients with small cell lung cancer met the inclusion criteria and were prospectively enrolled between November 2015 and September 2018.

Management information
Registered date
2015 Year 11 Month 06 Day
Last modified on
2019 Year 11 Month 14 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000022725